Cadrenal Therapeutics (CVKD) Common Equity (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Common Equity of $1.8 million for Q1 2026, down 34.38% sequentially from $2.7 million in Q4 2025, and down 70.6% YoY from $6.1 million in Q1 2025.
Cadrenal Therapeutics (CVKD) Common Equity (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Common Equity for 5 years, with the latest figure at $1.8 million in Q1 2026.
- Quarterly Common Equity fell 70.6% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 70.6% YoY) and the FY2025 annual result came in at $2.7 million, down 63.19% from the prior year.
- Common Equity slipped to $1.8 million in Q1 2026 per CVKD's latest filing, from $2.7 million in the prior quarter.
- Over five years, Common Equity peaked at $8.7 million in Q3 2023 and troughed at -$5.6 million in Q4 2022.
- A 5-year average of $3.2 million and a median of $3.4 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2026: Common Equity jumped 2503.39% in 2023, then sank 70.6% in 2026.
- Over 5 years, Common Equity stood at -$5.6 million in 2022, then surged by 238.57% to $7.7 million in 2023, then dropped by 3.29% to $7.4 million in 2024, then sank by 63.19% to $2.7 million in 2025, then tumbled by 34.38% to $1.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $1.8 million, $2.7 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Cadrenal Therapeutics | 4.59 Mn | 2.19 Mn | - | 4.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.09 Mn |
| Mar 31, 2026 | 1.80 Mn |
| Dec 31, 2025 | 2.74 Mn |
| Sep 30, 2025 | 2.73 Mn |
| Jun 30, 2025 | 4.30 Mn |
| Mar 31, 2025 | 6.11 Mn |
| Dec 31, 2024 | 7.44 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.99 Mn |
| Mar 31, 2024 | 6.19 Mn |
| Dec 31, 2023 | 7.69 Mn |
| Sep 30, 2023 | 8.75 Mn |
| Jun 30, 2023 | 3.18 Mn |
| Mar 31, 2023 | 4.07 Mn |
| Dec 31, 2022 | -5.55 Mn |
| Sep 30, 2022 | -1.18 Mn |
| Jun 30, 2022 | -670,838.00 |
| Mar 31, 2022 | -169,147.00 |